Bio-Convert Develops QR-02, a Potential Breakthrough in the Treatment of Oral Leukoplakia 

Rhea-AI Summary

Bio-Convert, a subsidiary of Nordicus Partners (OTCQB: NORD), has developed QR-02, a novel oral topical treatment for oral leukoplakia with moderate to severe dysplasia. The treatment addresses a significant market of 15.5 million patients in the U.S. and EU, where 10-30% of cases may develop into oral cancer.

QR-02's key innovation is its mucoadhesive formulation that adheres to the oral cavity for 12-24 hours, compared to traditional treatments lasting only 15-20 minutes. The treatment uses imiquimod, an FDA-approved active ingredient, in a unique oral application format. The product aims to treat and reduce dysplasia levels, potentially offering a curative solution for oral leukoplakia.

Positive

• Addresses large market opportunity of 15.5M patients in US and EU
• Innovative 12-24 hour mucoadhesive formulation vs. traditional 15-20 minute treatments
• Uses FDA-approved active ingredient (imiquimod) in new application
• Potential curative solution for condition with high cancer risk

Negative

• Product still requires clinical validation
• No timeline provided for clinical trials or market launch
• No data on treatment efficacy or success rates

BEVERLY HILLS, California, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Bio-Convert ApS (“Bio-Convert”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, announces the groundbreaking development of QR-02, a unique and proprietary oral topical treatment designed to address oral leukoplakia with moderate to severe dysplasia, a potentially precancerous condition affecting millions worldwide.

Addressing a Critical Unmet Medical Need

Oral leukoplakia is characterized by white patches or plaques in the mouth, and when accompanied by dysplasia (abnormal cell growth), it becomes a marker of disease progression. Alarmingly, 10-30% of these patients may develop oral cancer, which has a five-year mortality rate exceeding 50%.

With 15.5 million oral leukoplakia patients in the U.S. and EU alone, there is an urgent need for an effective treatment to prevent disease progression. Given that 80% of leukoplakia lesions occur in the oral cavity, a therapy that remains in place for an extended period is critical for success.

QR-02: A Game-Changing Approach

Bio-Convert’s QR-02 introduces a novel mucoadhesive oral formulation designed to adhere to the oral cavity for an extended period of 12-24 hours—a major advancement over traditional treatments, which last only 15-20 minutes due to the washout effect of saliva. This extended retention period significantly enhances drug efficacy and improves patient outcomes.

QR-02’s active ingredient, imiquimod, is already FDA-approved for treating Actinic Keratosis, External Genital Warts, and Superficial Basal Cell Carcinoma (sBCC)—all superficial skin conditions. However, QR-02 is uniquely formulated for oral application, providing new hope for patients with oral leukoplakia and may also be beneficial in treating conditions that subsequently could occur in such patients.

Potential for a Transformative Impact

The goal of QR-02 is to treat and reduce dysplasia levels, potentially offering a curative solution for oral leukoplakia, an outcome that would mark a significant breakthrough in oral medicine. By treating oral leukoplakia at an early stage, QR-02 may potentially have a positive health impact in patients with collateral symptoms.

Advancing Toward Clinical Validation

Bio-Convert is actively progressing QR-02 through its development pipeline, with plans to validate its efficacy through pilot clinical trials and bring this life-changing treatment to market. As Bio-Convert continues to push the boundaries of oral medicine innovation, QR-02 is a major step forward in preventing oral leukoplakia from developing into more severe conditions.

"We are incredibly proud of this invention and the impact it will have on patients," said Allan Wehnert, CEO & Founder of Bio-Convert. "Our hope is that patients may return to a normal life and, potentially, be cured of their illness."

For further information, contact:

Mr. Henrik Rouf
Chief Executive Officer
Phone +1 310 666 0750
Email hr@nordicuspartners.com

Investor Relations
Jonathan Paterson
Harbor Access Investor Relations
Jonathan.Paterson@Harbor-Access.com
Tel +1 475 477 9401

About Nordicus Partners Corporation

Nordicus Partners Corporation is the only U.S. publicly traded business accelerator and holding company for Nordic life sciences companies. Leveraging decades of combined management experience in domestic and global corporate sectors, Nordicus excels in corporate finance activities including business and market development, growth strategies, talent acquisition, partnership building, capital raising, and facilitating company acquisitions and sales. In 2024, Nordicus acquired 100% of Orocidin A/S, a Danish preclinical-stage biotech company developing next-generation therapies for periodontitis and 100% of Bio-Convert ApS, a Danish preclinical-stage biotech company dedicated to revolutionizing the treatment of oral leukoplakia. For more information about Nordicus, please visit: www.nordicuspartners.com, and follow us on LinkedIn, X, Threads and BlueSky.

Cautionary Note Regarding Forward-Looking Statements:

This press release may contain forward-looking statements that involve substantial risks and uncertainties. You can identify these statements by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “anticipate,” “project,” “estimate,” “intend,” “continue” or “believe” or the negatives thereof or other variations thereon or comparable terminology. You should read statements that contain these words carefully because they discuss our plans, strategies, prospects and expectations concerning our business, operating results, financial condition and other similar matters. We believe that it is important to communicate our future expectations to our investors. There may be events in the future, however, that we are not able to predict accurately or control. Any forward-looking statement made by us in this press release speaks only as of the date on which we make it. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

FAQ

What is Bio-Convert's QR-02 treatment for oral leukoplakia and how does it work?

QR-02 is a mucoadhesive oral formulation that uses imiquimod to treat oral leukoplakia. It adheres to the oral cavity for 12-24 hours, significantly longer than traditional 15-20 minute treatments, potentially improving efficacy.

What is the market size for NORD's oral leukoplakia treatment?

The market includes 15.5 million oral leukoplakia patients in the U.S. and EU combined, with 10-30% of cases at risk of developing oral cancer.

When will Bio-Convert's QR-02 begin clinical trials for NORD?

The press release indicates Bio-Convert is planning pilot clinical trials, but no specific timeline has been provided for the commencement of these trials.

What advantages does NORD's QR-02 have over existing treatments?

QR-02's main advantage is its extended adhesion time of 12-24 hours in the oral cavity, compared to traditional treatments that only last 15-20 minutes due to saliva washout.

How could QR-02 impact NORD's market position in oral medicine?

If successful, QR-02 could establish NORD as a leader in oral leukoplakia treatment, addressing an unmet medical need in a condition where current treatments have effectiveness.